|Type||Public KK (TYO: 4523)|
|Key people||Haruo Naito, President & CEO|
|Revenue||¥ 781.7 billion JPY (FY 2008)|
|Net income||¥ 47.7 billion JPY (FY 2008)|
Eisai Co., Ltd. (エーザイ株式会社 Ēzai Kabushiki-gaisha ) is a Japanese pharmaceutical company, ranking among the top 25 in the world by revenue and achieving $8 billion USD in sales for the fiscal 2008 year[ambiguous]. Headquartered in Tokyo, Japan, it has some 10,000 employees, among them about 1,500 in research. Eisai is a member of the Topix 100 and Nikkei 225 indices.
|This section needs additional citations for verification. (April 2011)|
Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995.
In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.
In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.
In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for $3.9 billion USD. This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.
Eisai maintains medical research headquarters in Woodcliff Lake, New Jersey as well as locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute is based.
The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.
Some of the key products that Eisai produces or markets with partners include:
- Aciphex/Pariet (rabeprazole) - Gastroesophageal reflux disease
- Actonel (risedronic acid) - Osteoporosis (Japan)
- Aloxi (palonosetron) - Chemotherapy-induced nausea and vomiting
- Aricept (donepezil) - Mild to moderate dementia for Alzheimer's Disease patients
- Banzel/Inovelon (rufinamide) - Seizures related to Lennox-Gastaut Syndrome
- Belviq (lorcaserin) - Obesity
- Fragmin (dalteparin) - Deep vein thrombosis and pulmonary embolism
- Fycompa (perampanel) - Partial-onset seizures
- Halaven (eribulin) - Metastatic breast cancer
- Iomeron - Non-ionic contrast medium
- Methylcobal - Peripheral neuropathy
- Myonal - Muscle relaxant
- Selbex - Gastric ulcers and gastritis
- Zonegran (zonisamide) - Partial-onset seizures
- Gliadel Wafer (carmustine)- Treatment for Brain Tumors
Along with these select prescription drugs, which account for 90% of the company's sales, Eisai markets Chocola BB, Travelmin, Nabolin, Juvelex, Saclon, and Selbelle tablets consumer products.
Aricept accounted for 40% of Eisai's revenue as of March 2010. The main competitor to Aricept is a generic formulation from Ranbaxy Labs. Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.
Some of Eisai's pipeline candidates include:
- AS-3201 - Diabetic neuropathy
- E2007 - Epilepsy & migrane prevention
- E5564 - Severe sepsis
- Michael Rosen, “Leading global Big Pharma companies of 2005”, WTN News, May 9, 2006.
- Kanoko Matsuyama (25 April 2011). "Eisai Aricept Patch for Alzheimer’s Isn’t Ready for Approval". Bloomberg. Retrieved 25 April 2011.